1. Name Of The Medicinal Product
Ultraproct® Ointment
2. Qualitative And Quantitative Composition
Each 1g of ointment contains:
Fluocortolone pivalate BP 0.92 mg
Fluocortolone hexanoate BP 0.95 mg
Cinchocaine hydrochloride BP 5.00 mg
3. Pharmaceutical Form
Ointment
4. Clinical Particulars
4.1 Therapeutic Indications
For the symptomatic relief of haemorrhoids and of pruritus ani in the short term (5-7 days).
4.2 Posology And Method Of Administration
Apply in a thin layer twice daily. In order to obtain a more rapid improvement, Ultraproct Ointment may be applied three or four times on the first day. The nozzle provided facilitates intrarectal application.
4.3 Contraindications
Viral infections. Primary bacterial or fungal infections. Secondary infections of the skin in the absence of appropriate anti-infective therapy. Known sensitivity to local anaesthetics.
4.4 Special Warnings And Precautions For Use
Warnings: In infants, long-term continuous therapy with topical corticosteroids should be avoided. Occlusion is not appropriate on the perineum. Adrenal suppression can occur even without occlusion. The application of unusually large quantities of topical corticoids may result in the absorption of systemically active amounts of corticoid. Secondarily-infected dermatoses definitely require additional therapy with antibiotics or chemotherapeutics agents. This treatment can often be topical but for heavy infections systemic antibacterial therapy may be necessary. If fungal infections are present, a topically active anti-mycotic should be applied.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
None known.
4.6 Pregnancy And Lactation
There is inadequate evidence of safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development, including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects on the human foetus.
4.7 Effects On Ability To Drive And Use Machines
None known.
4.8 Undesirable Effects
As with all topical steroids there is a risk of developing skin atrophy following extensive therapy.
Allergic skin reactions may occur.
4.9 Overdose
None stated.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Ultraproct contains the steroids fluocortolone hexanoate and fluocortolone pivalate, and the topically active local anaesthetic, cinchocaine hydrochloride.
Fluocortolone hexanoate: A topically active corticosteroid with the powerful anti-inflammatory properties of fluocortolone. Although its action is in less rapid onset than that of fluocortolone pivalate, it is more prolonged.
Fluocortolone pivalate: A rapid-acting ester of fluocortolone.
Cinchocaine hydrochloride: Has a local anaesthetic effect on mucous membranes and in combination with the above steroids provides quick relief of the painful and pruritic symptoms.
5.2 Pharmacokinetic Properties
Absorption and distribution: No data are available on the rectal absorption of fluocortolone hexanoate. The extent of the rectal absorption of fluocortolone pivalate is approximately 5% of the dose.
Metabolism: In-vitro and in-vivo investigations with corticosteroid esters (halogenated and non-halogenated corticoids) have shown that these compounds are split extremely rapidly into the corticoid and fatty acid through the esterases which are ubiquitously present in the body.
Elimination: No specific data are available on the elimination of fluocortolone hexanoate or fluocortolone pivalate in humans. However, it is known that corticosteroid metabolites are excreted in the urine.
5.3 Preclinical Safety Data
There are no preclinical safety data which could be of relevance to the prescriber and which are not already included in other relevant sections of the SPC.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Polyethylene glycol 400 monoricinoleate, castor oil, hydrogenated castor oil, 2- octyldodecanol, citrus rose perfume oil.
6.2 Incompatibilities
None known.
6.3 Shelf Life
Three years.
6.4 Special Precautions For Storage
Do not store above 25°C.
6.5 Nature And Contents Of Container
Tube of 30 g (OP)
6.6 Special Precautions For Disposal And Other Handling
Avoid inadvertent contact with the eyes. Wash hands carefully after use.
Keep out of the reach of children
7. Marketing Authorisation Holder
Schering Health Care Limited
The Brow
Burgess Hill
West Sussex RH15 9NE
8. Marketing Authorisation Number(S)
0053/5008R
9. Date Of First Authorisation/Renewal Of The Authorisation
31 March 1989/31 March 1994/31 March 1999
10. Date Of Revision Of The Text
8 September 1998
LEGAL CATEGORY
POM
